Methamphetamine Dependence Clinical Trial
Official title:
A Multiple-Center, Randomized, Double-Blind Study of Aripiprazole for Treatment of Methamphetamine Dependence
Methamphetamine substance use is common worldwide. No approved pharmacologic treatments for methamphetamine dependence exist. Aripiprazole are Second generation antipsychotics,but have different pharmacological effects of neurotransmitters.To determine whether mirtazapine would reduce methamphetamine use among mehtamphetamine addicts.
Status | Terminated |
Enrollment | 10 |
Est. completion date | February 2014 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 19 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Patients,Diagnostic and Statistical Manual of Mental Disorders 4thed. (DSM-IV) criteria for Methamphetamine dependence. 2. Must sign a Information consent form. 3. Required to provide detailed address and phone number Exclusion Criteria: 1. Serious organic disease. 2. Suicide ideation or hurt others. 3. Taking antipsychotic within two weeks before. 4. drug allergy to Risperidone or Aripiprazole. 5. pregnancy and breastfeeding women. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | The Second Xiangya Hospital of Central University | Changsha | Hunan |
Lead Sponsor | Collaborator |
---|---|
Wei Hao |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | abstinent time of Methamphetamine addict | methamphetamine-positive urine test results,self-reports of substance use | up to 3 months | Yes |
Secondary | number of Participants with Adverse Events as a Measure of Safety and Tolerability | use Abnormal Involuntary Movement Scale ,Simpson-Angus Scale and Barnes akathisia Scale | up to 3 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00984360 -
Study of Naltrexone for Methamphetamine Addiction
|
Phase 2 | |
Completed |
NCT01685463 -
Transcranial Magnetic Stimulation Used to Both Measure Cortical Excitability and Explore Methamphetamine Cue Craving
|
N/A | |
Completed |
NCT00569374 -
Safety and Tolerability of Modafinil for Methamphetamine Dependence
|
Phase 2 | |
Completed |
NCT01967381 -
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse
|
Early Phase 1 | |
Completed |
NCT01354470 -
A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence
|
Phase 2 | |
Active, not recruiting |
NCT01044238 -
Methylphenidate to Treat Methamphetamine Dependence
|
Phase 2 | |
Terminated |
NCT01019707 -
Safety Assessment of Atomoxetine With MA IV Administration
|
Phase 1 | |
Completed |
NCT01215929 -
Studying Amphetamine Withdrawal in Humans
|
Phase 2 | |
Completed |
NCT00227123 -
A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence
|
N/A | |
Recruiting |
NCT02568878 -
Creatine for Depressed Male and Female Methamphetamine Users
|
Phase 3 | |
Completed |
NCT01007539 -
Efficacy and Safety of CDP-choline in Patients With Methamphetamine Dependence
|
Phase 3 | |
Completed |
NCT01011829 -
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence
|
Phase 2 | |
Completed |
NCT01062451 -
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
|
Phase 1 | |
Completed |
NCT00687713 -
Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence
|
Phase 2 | |
Completed |
NCT01063205 -
NAC as a Potential Treatment for Methamphetamine Dependence
|
Phase 1 | |
Completed |
NCT02058966 -
Pilot Study of Entacapone for Methamphetamine Abuse
|
Early Phase 1 | |
Completed |
NCT00332605 -
N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence
|
Phase 2 | |
Completed |
NCT01860807 -
Trial of Ibudilast for Methamphetamine Dependence
|
Phase 2 | |
Terminated |
NCT01813643 -
A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis
|
Phase 4 | |
Completed |
NCT01073319 -
Rivastigmine as a Treatment for Methamphetamine Dependence
|
Phase 1 |